ZENTALIS PHARMACEUTICALS INC
1 day chart
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a focused pipeline of oncology candidates. The Company’s product candidates include Azenosertib (ZN-c3), a Wee1 inhibitor for advanced solid tumors and hematological malignancies; ZN-d5, a B-cell lymphoma 2 (BCL-2), inhibitor for hematological malignancies and related disorders; and a heterobifunctional degrader of BCL-xL, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. The Company is evaluating azenosertib and ZN-d5 in multiple ongoing clinical trials and conducting studies to enable an Investigational New Drug (IND), application for its BCL-xL product candidate. The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Buy US stocks in Australia starting with ZNTL. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ZNTL
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.